文献速递临床免疫质量管理与危急值

前列腺特异性抗原检测方法间偏倚对活检转诊的影响:迈向精准健康管理的关键

Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management.
PubMed 文献 · Clin Chem Lab Med · 2022-11-02

该研究评估了四种免疫分析平台(Abbott、Beckman、Roche、Siemens)检测总PSA(tPSA)和游离PSA(fPSA)的方法间偏倚,并尝试将基于Roche方法的tPSA风险阈值转换为其他方法的对应浓度。研究还评估了偏倚对%f/tPSA比值的影响,并对%f/tPSA比值的阈值进行了重新校准。结论是若不应用适当的转换因子,存在漏诊晚期前列腺癌的风险。

要点

  • 不同免疫分析平台间tPSA和fPSA检测存在线性但非恒定的偏倚。
  • Siemens和Abbott相对Roche和Beckman对%f/tPSA比值倾向于高估。
  • 不应用转换因子可能导致晚期前列腺癌漏诊风险。

核心结论

  • 方法间偏倚呈线性,允许将Roche的PSA结果转换为其他方法的结果。
  • 不应用适当转换因子存在漏诊晚期前列腺癌的风险。

研究设计与样本

  • 在135份和137份血清样本中分别用Abbott Alinity i、Beckman Access Dxl、Roche Cobas e801和Siemens Atellica IM平台检测tPSA和fPSA。
  • 使用散点图、Bland-Altman图和Passing-Bablok回归评估方法间系统性和比例偏倚。

主要发现

  • Siemens和Abbott相对Roche和Beckman对tPSA和fPSA测量具有正和负比例偏倚,倾向于高估%f/tPSA比值。
  • 其他方法相对Roche低估tPSA。

关键数值与推荐

  • 使用线性方程及参数估计的置信区间将基于Roche的tPSA风险阈值转换为其他方法的对应浓度。
  • 使用Passing-Bablok和非参数bootstrapping构建校正系数以转换%f/tPSA比值。

临床怎么用

  • 临床解读PSA结果时应考虑检测方法间的偏倚,必要时应用转换因子。
  • 对于基于特定方法建立的风险阈值,在换用其他方法时应进行重新校准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We assessed the inter-method bias of total (tPSA) and free (fPSA) prostate-specific antigen (PSA) immunoassays to establish if tPSA-based risk thresholds for advanced prostate cancer (PCa), obtained from one method (Roche) can be converted into the corresponding concentrations assayed by other methods. Then we evaluated the impact of the bias of tPSA and fPSA on the estimation of the %f/tPSA ratio and performed a re-calibration of the proposed thresholds for the %f/tPSA ratio according to the assay used. METHODS: tPSA and fPSA were measured in 135 and 137 serum samples, respectively by Abbott Alinity i, Beckman Access Dxl, Roche Cobas e801, and Siemens Atellica IM analytical platforms. Scatterplots, Bland-Altman diagrams, Passing-Bablok (PB) were used to inspect and estimate the systematic and proportional bias between the methods. The linear equations with confidence intervals of the parameter estimates were used to transform the tPSA risk thresholds for advanced PCa into the corresponding concentrations measurable by the other analytical methods. To construct a correction coefficient for converting the %f/tPSA ratio from one method to the other, PB and non-parametric boostrapping were used. RESULTS: The inter-method bias is not constant but strictly linear allowing the conversion of PSA results obtained from Roche into the other assays, which underestimate tPSA vs. Roche. Siemens and Abbott vs. Roche and Beckman assays, being characterized by a positive and a negative proportional bias for tPSA and fPSA measurements, tend to overestimate the %f/tPSA ratio. CONCLUSIONS: There is a consistent risk to miss advanced PCa, if appropriate conversion factors are not applied.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Ferraro S, Biganzoli G, Bussetti M, et al. Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management. Clin Chem Lab Med. 2022. PMID: 36322977. doi:10.1515/cclm-2022-0874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。